5/1/2017 1 Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead, Bayer 2) Consultant: Actelion, Gilead, United Therapeutics, Bayer, Bellerephon 3) Research Grants: United Therapeutics, Gilead, Actelion
18
Embed
Disclosures - NAMCP Farber.pdf · Boston University School of Medicine ... Honoria: Actelion, Gilead, Bayer 2) Consultant: Actelion, Gilead ... Most long-term data come from open-label
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
5/1/2017
1
Effective Strategies and Clinical Updates in Pulmonary Arterial
Hypertension
Hap Farber Director, Pulmonary Hypertension Center
Boston University School of Medicine
Disclosures
1) Honoria: Actelion, Gilead, Bayer 2) Consultant: Actelion, Gilead, United Therapeutics, Bayer, Bellerephon3) Research Grants: United Therapeutics, Gilead, Actelion
5/1/2017
2
Discussion today
1) Identify the latest recommendations and clinical guidelines for the management of patients with PAH 2) Explore the advances in the diagnostic algorithm for PH3) Evaluate the latest data on oral prostanoids and how they can be incorporated into appropriate treatment plans4) Discuss effective therapeutic strategies to modify treatment for patients with worsening PAH despite existing therapy5) Analyze the differences between conventional and emerging PAH therapies based on current evidence for their efficacy, safety, and utility
Discussion today
Choice of treatment for PAH: what we do and why do we do it this way?
5/1/2017
3
Treatment Issues in PAH
1) One, two, or three drugs?
Monotherapy
Dual combination therapy
Triple combination therapy
2) When?
Upfront
Add-on (stable vs. failing)
3) Which drugs and in what order?
1. Pulmonary arterial hypertension
1.1 Idiopathic PAH1.2 Heritable PAH1.2.1 BMPR21.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK31.2.3 Unknown1.3 Drug and toxin induced1.4 Associated with:1.4.1 Connective tissue disease1.4.2 HIV infection1.4.3 Portal hypertension1.4.4 Congenital heart diseases1.4.5 Schistosomiasis
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis1′′ Persistent pulmonary hypertension of the newborn (PPHN)
Classification of Pulmonary Hypertension (Nice, 2013)
5/1/2017
4
Classification of Pulmonary Hypertension (Nice, 2013)
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction2.2 Left ventricular diastolic dysfunction2.3 Valvular disease2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease 3.2 Interstitial lung disease3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 3.4 Sleep-disordered breathing3.5 Alveolar hypoventilation disorders3.6 Chronic exposure to high altitude3.7 Developmental lung disorders
Classification of Pulmonary Hypertension (Nice, 2013)
Calcium Channel Blockers1) Small subset (<<10%) of patients with IPAH have favorable long-term
response to high-dose CCB2) Potential patients identified by reduction in mPAP ≥10 with absolute
mPAP <40 and increased or unchanged CO3) Vasoreactivity testing only performed with short-acting pulmonary
vasodilators (iNO currently agent of choice)
4) Slow up-titration with CCB required with high level maintenance doses(Diltiazem, 240–720mg; nifedipine, 120–240mg)
5) Patients without sustained hemodynamic response to NYHA FC I or II require other PAH therapy
Humbert M, et al. Circulation 2014; 130:2189-2208Sitbon O, et al. Circulation 2005; 111:3105–11
REVEAL: Monotherapy and Combination Therapy in Patients with PAH
Badesch DB, et al. Chest 2010; 137;376-87.
N = 2438. Treatment reported at time of enrollment in REVEAL
18.50% 17.10%11.10%
0.90%
21.10% 24.40%16.10%
5.80%7.40% 7.50% 4.80% 3.00%
0%
20%
40%
60%
80%
100%
ERA PDE51 IV/SCProstacyclin
InhaledProstacyclin
Per
cent
(%
)
Monotherapy Dual Combination Triple Combination
48% of patients were receiving monotherapy at the time of study enrollment.
5/1/2017
8
Use of Parenteral Prostanoids at Time of Death in the REVEAL Registry
Farber H, et al. J Heart Lung Transpl 2013; 32:1114-22.
N=909. All-cause mortality.
16%
Total IV/SC prostanoid therapy use = 43.0%
12%
8%
4%
0%
7.6%8.4%
14.4%11.2%
1.1%
5.6%3.0%
12.4%
15.1%
4.6%
11.2%
5.3%
REVEAL: Under-use of Parental Prostanoids in FC IV PAH
5.8%
43.2%51.0%
IV Prostacyclin Use 1 Day Prior to
Designation as FC IVPGI MonotherapyPGI Combination TherapyNo PGI
52.0%48.0%
IV/SC Prostacyclin Use 90 Days After
Designation as FC IV
PGI Therapy No PGI
Farber H, et al. J Heart Lung Transpl 2013; 32:1114-22.
N=294 patients worsening to FC IV.
5/1/2017
9
PAH Long-term Monotherapy Trials: Caveats
1) Most long-term data come from open-label extensions of placebo-controlled trials (no comparator arm)
2) These trials allowed add-on therapy after initial blinded treatment phase; thus, some or all of the efficacy seen in open-label phase could be due to add-on therapy, not “primary” study medication
3) Some trials defined add-on therapy as a clinical endpoint; others did not
4) Results cannot be compared across studies because each trial was unique, with fundamental protocol differences (study size, FC, outcomes definitions, use of additional medications without reaching trial endpoint, etc.)
PAH Long-term Combination Therapy Trials: Caveats
1) Only AMBITION prospectively studied the question of monotherapy versus de novo combination therapy
2) All other currently reported trials featured “add-on” protocols
3) Relative contribution of individual agents to treatment success difficult to assess
4) Combination therapy trials often have only a short-term component, with no long-term follow-up
5/1/2017
10
AMBITION: Ambrisentan-Tadalafil Combination Therapy. Primary Study Endpoint: Time To Clinical Worsening
Primary Endpoint: Time to First Clinical Failure Event
0
25
50
75
100
Eve
nt-
Fre
e (%
)
Time (weeks)0 24 48 72 96 120 144 168 192
1 year 88.9%
1 year 75.5%
Combination therapyPooled monotherapy
2 year 79.7%
2 year 63.2%3 year 56.1%
3 year 67.6%
Combination: 253 229 186 145 106 71 36 4
Pooled monotherapy: 247 209 155 108 77 49 25 5
Number at risk:
Nazzareno G, et al. ERS 2014
Galiè N et al. N Engl J Med 2015;373:834-844.
Kaplan–Meier Curves for the Probability of a First Adjudicated Primary End-Point Event.
Upfront triple combination therapy in PAH: a pilot study
Sitbon O, et al. Eur Resp J 2014; 43:1691-7.
28Galiè N et al. Eur Heart J 2015:doi:10.1093/eurheart/ehv317.
ESC/ERS 2015 treatment algorithm for PAH
5/1/2017
15
29
ESC/ERS 2015 recommendations for monotherapy in PAH
Galiè N et al. Eur Heart J 2015:doi:10.1093/eurheart/ehv317.
30
ESC/ERS 2015 recommendations for upfront and sequential combination therapy in PAH
Galiè N et al. Eur Heart J 2015:doi:10.1093/eurheart/ehv317.
Upfront Sequential
Consideration: Dose adjustments and potential side effects may be simpler to manage with sequential administration of combination partners
5/1/2017
16
Treatment Issues in PAH
1) One, two, or three drugs?
Monotherapy
Dual combination therapy
Triple combination therapy
2) When?
Upfront
Add-on (stable vs. failing)
3) Which drugs and in what order?
Anticoagulation
1) Anticoagulation recommended in PAH with vitamin K antagonist1 (INR of 1.5-2.5, unless contraindicated). No evidence for NAC.
2) Small observational studies support survival benefit of anticoagulation in IPAH2-4
3) Survival benefit recently suggested by COMPERA trial in EU5
4) Improvement in survival not observed in other forms of APAH (such as SSc)
5) Anticoagulation warranted to minimize catheter-related thrombosis in those receiving continuous intravenous prostanoid therapy
1. Humbert M, et al. Circulation 2014;130: 2189-22082. Rich S, et al. NEMJ 1992; 327:76–813. Frank H, et al. Chest 1997; 112:714–21 4. Fuster V, et al. Circulation 1984; 70:580–75. Olsson KM, et al. Circulation 2014; 129:57–65
5/1/2017
17
Anticoagulation: Kaplan-Meier estimates of survival at 36 months for IPAH patients.
IPreston et al. Circulation 2015; 132:2403-11
Anticoagulation: Kaplan-Meier estimates of survival at 36 months for SSc-PAH patients.
Preston et al. Circulation 2015; 132:2403-11
5/1/2017
18
Summary: Long-term Management of Patients With PAH
1) Availability of oral, inhaled, and parenteral PAH therapies provides multiple treatment strategies for patients with PAH; trend toward multi-drug therapy
2) Long-term data on choice of initial medical therapy, de novo combination therapy, or therapy sequencing are still incomplete
3) Considerations for initial therapy selection and for combining therapies should take into account consensus recommendation/guidelines, long-term efficacy and safety data, second-line choices, and patient characteristics, with an individualized approach for each patient
4) In patients with severe disease or in those failing medical therapy, early referral to PAH centers for advanced therapy important
5) Anticoagulation: not sure for IPAH; definite no for scleroderma/CTD